Tango Therapeutics TNGX TNG456Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's tng456direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's tng456direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported tng456direct program expenses-rd — research and development expense of $2.06M in Q1 2026.
- How has Tango Therapeutics's tng456direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's tng456direct program expenses-rd — research and development expense increased by 55.8% year-over-year, from $1.32M to $2.06M.
- What does tng456direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development costs specifically allocated to the TNG456 clinical or preclinical program. It captures the internal and external expenditures required to advance this specific oncology asset through its development lifecycle, including laboratory testing, clinical trial execution, and regulatory preparation. Tracking this expense allows investors to assess the capital intensity and investment priority of this particular drug candidate within the company's broader precision medicine pipeline.